- Home
- IBO vs IBIO Comparison
IBO vs IBIO Comparison
Compare IBO & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBO
- IBIO
- Stock Information
- Founded
- IBO 2018
- IBIO 2008
- Country
- IBO United States
- IBIO United States
- Employees
- IBO N/A
- IBIO N/A
- Industry
- IBO
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- IBO
- IBIO Health Care
- Exchange
- IBO NYSE
- IBIO Nasdaq
- Market Cap
- IBO 22.1M
- IBIO 24.3M
- IPO Year
- IBO 2024
- IBIO N/A
- Fundamental
- Price
- IBO $2.12
- IBIO $3.48
- Analyst Decision
- IBO
- IBIO Strong Buy
- Analyst Count
- IBO 0
- IBIO 3
- Target Price
- IBO N/A
- IBIO $4.87
- AVG Volume (30 Days)
- IBO 23.0K
- IBIO 299.1K
- Earning Date
- IBO 03-04-2025
- IBIO 02-10-2025
- Dividend Yield
- IBO N/A
- IBIO N/A
- EPS Growth
- IBO N/A
- IBIO N/A
- EPS
- IBO 0.01
- IBIO N/A
- Revenue
- IBO N/A
- IBIO $375,000.00
- Revenue This Year
- IBO N/A
- IBIO $36.00
- Revenue Next Year
- IBO N/A
- IBIO $33.33
- P/E Ratio
- IBO $175.47
- IBIO N/A
- Revenue Growth
- IBO N/A
- IBIO 650.00
- 52 Week Low
- IBO $1.16
- IBIO $1.05
- 52 Week High
- IBO $3.25
- IBIO $4.98
- Technical
- Relative Strength Index (RSI)
- IBO N/A
- IBIO 55.25
- Support Level
- IBO N/A
- IBIO $3.22
- Resistance Level
- IBO N/A
- IBIO $3.76
- Average True Range (ATR)
- IBO 0.00
- IBIO 0.38
- MACD
- IBO 0.00
- IBIO 0.00
- Stochastic Oscillator
- IBO 0.00
- IBIO 56.41
About IBO IMPACT BIOMEDICAL INC
Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The Company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.